Journal
DIAGNOSTICS
Volume 8, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics8020031
Keywords
circulating tumor cells; single cell analysis; deep-sequencing; liquid biopsy; cancer diagnosis; cancer treatment
Categories
Funding
- European Research Council [678834]
- European Commission [801159]
- Swiss National Science Foundation [PP00P3_163938, PZ00P3_168165]
- Swiss Cancer League [KFS-3811-02-2016, KLS-4222-08-2017, KFS-3995-08-2016]
- Basel Cancer League [04-2015, KlbB-4173-03-2017, KLbB-4183-03-2017]
- Basel through the ETH Zurich [PMB-01-16]
- University of Basel
Ask authors/readers for more resources
The field of cancer diagnostics has recently been impacted by new and exciting developments in the area of liquid biopsy. A liquid biopsy is a minimally invasive alternative to surgical biopsies of solid tissues, typically achieved through the withdrawal of a blood sample or other body fluids, allowing the interrogation of tumor-derived material including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) fragments that are present at a given time point. In this short review, we discuss a few studies that summarize the state-of-the-art in the liquid biopsy field from a diagnostic perspective, and speculate on current challenges and expectations of implementing liquid biopsy testing for cancer diagnosis and monitoring in the clinical setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available